The Thesis
PanicFade v4 is a contrarian mean-reversion strategy built on a simple, well-documented behavioural premise: negative headline shocks tend to be overreacted to and subsequently revert toward fundamentals. Concretely, it buys names hit by sentiment below −0.4 that are already oversold — RSI14 under 35 and trading below their 20-day SMA — and sizes into the panic. Exits are equally rule-bound: it takes profit on reversion (RSI14 back above 50 or price reclaiming the SMA20) and hard-stops fresh lows under continued negativity, treating persistent weakness as a genuine fundamental break rather than noise.
The design cites the 2025 q-fin literature on sentiment feedback and asymmetric retail overreaction (arXiv:2509.11970), and it plays only in a 24-name large-cap universe spanning tech, financials, staples, healthcare and energy. That constraint matters — fading panic is far safer in liquid, well-covered mega-caps than in the small caps where sentiment shocks can signal real distress.
Validation
This is where PanicFade v4 earns its keep. Across four sequential walk-forward folds from September 2021 to August 2026, every fold was positive (4/4), with returns accelerating through the sample: 1.6%, 3.88%, 10.14%, and 21.7%. The most recent out-of-sample fold posted a 2.44 Sharpe against just a 2.6% max drawdown — an unusually clean tail. Headline validation stats are strong: a Probabilistic Sharpe Ratio of 0.985 and a Deflated Sharpe Ratio of 0.56 after accounting for 27 trials. The DSR staying comfortably positive after that many attempts is the single most reassuring number here, since it directly discounts the risk that the result is a data-mining artefact.
Full-Period Performance and the Caveats
On the full backtest, the strategy returned 37.93% over 1,233 days — but that annualises to a modest 6.79% CAGR, with an overall Sharpe of 0.96 and a 9.3% max drawdown. The 62.88% win rate across 530 trades is healthy for a mean-reversion book. Two things temper the enthusiasm. First, turnover is enormous at 5,807%, meaning the edge lives or dies on execution and fee assumptions holding up in reality. Second, the whole-period Sharpe under 1.0 is a reminder that the eye-catching 2.44 belongs to one recent fold, not the strategy's baseline.
It's also worth noting the Improver module failed to beat this configuration after three attempts — a mild vote of confidence that v4 is already near a local optimum, but not evidence it can be pushed further.
Live So Far: Silence
Deployed 2026-08-06 with $10,000 and approved at risk 0.35, PanicFade v4 has now logged three scheduled runs — deployment day plus 06 and 07 August — with zero trades executed, zero rejected, cash and total equity flat at $10,000. That is not a malfunction; it is the strategy working as designed. Its entry conditions require a genuine sentiment-and-price panic to coincide, and a calm early-August tape simply hasn't offered one.
Verdict
PanicFade v4 is a rare thing: a live strategy with a coherent behavioural thesis, honest walk-forward validation, and the patience to sit in cash. The risks are execution-cost sensitivity from high turnover and a real-world track record that is, so far, a blank page. The interesting test comes with the next market scare.